COMy 2021 | Unmet needs in WM management: MYD88 WT and CXCR4 MUT disease
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, talks on the challenges posed by MYD88 WT and CXCR4 MUT status in Waldenström’s macroglobulinemia (WM). MYD88WT typically confers a more aggressive disease course, with patients showing poorer responses to BTK inhibitors and shorter overall survival. Similarly, patients with mutated CXCR4 show less deep responses to BTK inhibition, as well as shorter progression-free survival. Dr Treon discusses investigations underway to address the unmet needs in these genomic subtypes. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Research funding and consulting fees: Janssen, Abbvie/Pharmacyclics, Beigene, X4
Research funding: Eli Lilly
